Key Points Interested in Nautilus Biotechnology, Inc.? Here are five stocks we like better. Nautilus is shifting most R&D ...

GATE 2027 Biotechnology syllabus has been revised with major additions in biology, genetics, plant biotechnology and ...

Buffett’s casino comments raise an uncomfortable truth. Is biotechnology an investment, or is it more of a gambling casino?

SC451 for type 1 diabetes drives upside, but valuation & dilution risk loom. Click here to read more about the SANA stock.

Ruypeptide Biotechnology Co., Ltd.** is expanding its international presence by strengthening its biotechnology research capabilities, manufacturing capacity, and global customer support as demand for ...

Biotechnology investors remain confident in the sector's outlook even after a major comeback this year — and they're picking ...

Do you want to be at the forefront of the rapidly growing biotechnology field? Do you want to develop products derived from living organisms and biomolecules? Do you have a passion for biochemistry, ...

"Biotechnology" is a term commonly applied to the development of new medicines and therapies, the development of genetically modified plants, biofuels, biological treatment, or the production of ...

See the U.S. News rankings for Biotechnology and Applied Microbiology among the top universities in United States. Compare the academic programs at the world's best universities.

Biotech remains one of the market's more out-of-favor sectors despite improving industry fundamentals. Here are three stocks trading near multiyear lows.

Sana Biotechnology's lead asset still remains to be SC291, repurposed for severe autoimmune disorders instead of blood ...

Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2026.